Alvotech定价8500万美元股票发行，计划通过私募进行额外融资

• Alvotech (ALVO) priced its previously announced underwritten public offering of 22.67M ordinary shares at $3.75 per share, expecting to raise about $85M in gross proceeds.
• The global biosimilars developer also granted underwriters a 30-day option to purchase up to an additional 3.4M shares.
• Separately, Alvotech entered into subscription agreements with certain institutional investors in the European Economic Area to sell 17.83M ordinary shares at the same price of $3.75 per share in a concurrent private placement, expected to generate about $67M in gross proceeds.
• Combined, the public offering and private placement are expected to raise approximately $152M, or up to $165M if underwriters fully exercise their option.
• The public offering is expected to close on or around June 17, while the private placement is expected to close on or around June 25.
• Net proceeds will be used to advance development of its biosimilar pipeline and support general corporate purposes, including intellectual property protection, commercialization efforts, capital expenditures, acquisitions or collaborations, research and development activities, pre-commercialization initiatives, and repayment or refinancing of debt.
• The stock price slumped about 8% on Monday during after-market hours of trading.

More on Alvotech

• Alvotech (ALVO) Presents at UBS Virtual Generics and Biosimilars Day Transcript
• Alvotech (ALVO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Alvotech: Speculative 'Buy' Despite The FDA's CMC Requirements
• Alvotech initiates $125M fundraising via public and private offering for biosimilar growth
• Biggest stock movers Monday: NRIX, INTC, and more